NCT05249556: An ongoing trial by Immedica Pharma AB
This trial is ongoing. It must report results 3 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05249556 |
|---|---|
| Title | Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone in the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2026 |
| Completion date | Sept. 30, 2028 |
| Required reporting date | Sept. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |